SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group (NBIS) is trending as a critical local council vote unfolds on a massive AI data center project in Independence, Missouri, igniting intense community debate over its substantial economic prospects versus local concerns, while market sentiment also contends with broader sector volatility and geopolitical tensions impacting AI infrastructure plays.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending with high volume and price appreciation due to escalating Middle East tensions, including threats to the Strait of Hormuz and attacks on regional energy infrastructure, leading the community to speculate on its continued upside compared to other oil plays.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is surging amid institutional investment, notably a hedge fund stake, and growing recognition from partners like Quantum Computing and Sivers, fueling community excitement over its disruptive optical interconnect technology crucial for scaling AI infrastructure and a forecasted strong revenue ramp.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil (BATL) is seeing extreme trading volume and a rapid price increase, driven by escalating geopolitical tensions in the Middle East that are propelling oil prices higher. The community is buzzing about a potential short squeeze, fueled by reports of high borrowing costs and a scarcity of shares available for shorting.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending after its recent earnings report, which, despite strong performance, included weaker-than-expected forward guidance and leadership changes, triggering a sharp stock decline. The community is split between those who view the pullback as an overblown reaction and a buying opportunity, and others who believe the valuation adjustment is justified.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment Inc. (AVAV) is sharply lower after a Raymond James downgrade, citing recompetition for a key Space Force contract, triggered a massive intraday sell-off and intensified community debate over market manipulation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group Inc. is trending after announcing record annual revenue for 2025 and a major profitability turnaround, alongside a significant AI infrastructure pipeline and a recent MoU in Saudi Arabia. The community is actively debating whether these strong fundamentals position the deeply undervalued stock for a re-rating or if past skepticism and ongoing short interest will continue to weigh on its price.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following a recent strategic collaboration aimed at deploying significant fuel cell power for rapidly expanding AI data centers, positioning its molten carbonate technology as a key solution for critical energy demands. While optimism builds around its potential to secure substantial contracts in this booming sector, the community remains divided, with some drawing comparisons to successful peers and others expressing skepticism given the company's past performance and ongoing share dilution.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending due to Nvidia's significant investment and strategic partnership to advance optical interconnects for AI data centers, driving community excitement around photonics as the new AI infrastructure frontier, despite some debates over its rapid valuation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is trending after the FDA stated its gene therapy for Huntington's disease, AMT-130, lacks sufficient data for a BLA and is recommending a sham surgery-controlled study. This decision has sparked community debate over the agency's strict stance and potential delays for a critical treatment, with many criticizing the ethical implications of a sham trial for such a debilitating condition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference PR Newswire...

<ul class="summary-bullets"><li>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.</li><li>The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.</li><li>Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for Imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP).The company noted that if the FDA approves its application, Imsidolimab could address a significant unmet medical need in this rare and life-threatening disorder.<a href="https://stocktwits.com/symbol/VNDA">Vanda shares</a> were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Vanda Says Over Half Of Patients Achieved Clear Or Almost Clear Skin</h2>Vanda noted that in the Gemini-1 and Gemini-2 studies evaluating the efficacy of Imsidolimab, more than half of the patients achieved clear or almost clear skin by the fourth week, compared to 13% on placebo.The company said that efficacy was maintained throughout an approximately 2-year maintenance period with monthly doses, and no flares occurred in the active treatment arm.Vanda added that GPP is a rare disorder with prevalence estimates varying widely by region, ranging from approximately 2 to 124 cases per million worldwide.“Imsidolimab builds on our growing expertise in rare orphan disorders and our anti-inflammatory portfolio. Imsidolimab represents a precision medicine approach targeting a disorder with a known genetic cause using a fully humanized monoclonal antibody against the IL-36 receptor,” said Vanda CEO Mihael H. Polymeropoulos.<h2 class="st-heading-2">What Does Vanda Do?</h2>Vanda Pharmaceuticals is a Washington-based biopharmaceutical company focused on the development and commercialization of therapies that cater to highly unmet medical needs.Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling. The company expects regulatory and patent exclusivity for the treatment to extend into the late 2030s.<a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is down 7% year-to-date, but up 88% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder

Vanda Pharma company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

Equity

The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis Vanda Pharmaceuticals Announces FDA...

Small Cap Stocks To Research - February 23rd

AltC Acquisition, Vanda Pharmaceuticals, Spring Valley Acquisition, Direxion Daily PLTR Bear 1X Shares, Direxion Daily TSLA Bear 1X Shares, Veris Residential, and Vale are the seven Small Cap stocks...

Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) saw some unusual options trading activity on Monday. Traders bought 13,610 call options on the company. This represents an increase of 596...

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets

Futures Slide As Renewed Tariff Turmoil Shakes Global Markets Stock futures slumped after Trump's weekend tariff tantrum added uncertainty to American trade policy and was another blow to bullish...

Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket

<ul class="summary-bullets"><li>President Donald Trump announced over the weekend that global tariffs would rise from 10% to 15%.&nbsp;</li><li>Traders are also watching last-ditch nuclear negotiations with Iran scheduled in Geneva later this week.&nbsp;</li><li>Nvidia earnings later this week could define the next leg of the market.</li></ul>U.S. stock futures were sharply lower early Monday as investors grappled with a renewed tariff uncertainty, rising geopolitical tensions with Iran, and awaited Nvidia's big earnings report later this week. Last week’s momentum is being tested by President Donald Trump’s announcement over the weekend of a hike in global tariffs from 10% to 15%, which came a day after the Supreme Court struck it down as ‘anti-American.’The markets are also watching last-ditch nuclear talk attempts with Iran in Geneva this Thursday, amidst reports that the U.S. is considering significant military action if diplomacy fails.&nbsp;As of 3:00 a.m. ET on Monday, Nasdaq futures fell 0.6%, the S&amp;P 500 and Dow futures declined 0.5%, while Russell 2000 futures were down nearly 1%.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘bearish’ from ‘neutral’ last week, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;On the other hand, precious metals have seen a breakout, with gold rising above $5,100 and silver nearing $88/oz.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chip giant reports earnings on Feb 25. Beyond its guidance, all eyes will be on its commentary on AI hype, investments, and sustainability.Netflix (NFLX):&nbsp;The stock is facing potential downward pressure after President Trump threatened consequences if board member Susan Rice is not removed. This adds another layer of uncertainty as it pursues its bid for Paramount Skydance (PSKY).&nbsp;Honeywell (HON):&nbsp;It has entered into an amended deal to acquire Johnson Matthey’s Catalyst Technologies business for $1.8 billion.Vanda Pharmaceuticals (VNDA):&nbsp;The US FDA has approved Bysanti for bipolar I disorder and schizophrenia.Moonlake Immunotherapeutics (MLTX):&nbsp;Positive Phase 2 data for its spinal disease drug have led to strong after-hours gains. Traders will be watching this stock closely as we head into a new week.&nbsp;Immunity Bio (IBRX):&nbsp;This biotech stock continues to garner retail attention. Executive chairman Patrick Soon-Shiong&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us">teased</a> a detailed three-year expansion roadmap, with a detailed press release expected on Monday.&nbsp;Deere &amp; Co (DE):&nbsp;One of the most actively traded stocks last week saw a downgrade to ‘Underperform’ from Jefferies, with a target price of $550. The analyst believes it is already ‘discounted a full recovery’ and trades at steep valuations.&nbsp;Rolls-Royce (RYCEY): The company is reportedly preparing a buyback program of up to €1.5 billion.Other tickers trending on Stocktwits at the time of writing included Capricor Therapeutics (CAPR), Kraft Heinz Co (KHC), Oklo Inc (OKLO), and Ardelyx (ARDX), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of factory orders at 10:00 am ET. They will also be watching for commentary from Fed Governor Christopher Wallace before the bell today.&nbsp;On the earnings radar, investors will be watching for the quarterly reports from Domino’s Pizza (DPZ), GeneDX (WGS), Freshpet (FRPT), and Dominion Energy (D), among others, before the bell&nbsp;today. Also watch out for Hims &amp; Hers (HIMS), Keysite Technologies (KEYS), and Diamonback Energy (FANG) that report after market close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 

<ul class="summary-bullets"><li>Three of four analysts on Koyfin rate the stock ‘Buy,’ with a 12-month target of $13.63, implying 137% upside from the last close.</li><li>The next catalysts include a Phase 3 depression study for Bysanti and a Phase 3 GLP-1 nausea trial for Tradipitant.</li><li>A mid-2026 FDA decision for Imsidolimab in skin disease is also due, along with continued development of Hetlioz across other sleep indications.</li></ul>Shares of Vanda Pharmaceuticals, Inc. (VNDA) jumped over 40% in overnight trading on Sunday after the U.S. Food and Drug Administration (FDA) approved its Bysanti tablets, putting the stock back into the spotlight as investors weigh what could drive the next leg higher.The&nbsp;stock surged&nbsp;45% in after-hours trading on Friday after the FDA cleared Bysanti for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. Vanda said it expects the drug to be available in the market in the third quarter of 2026.<h2 class="st-heading-2">VNDA: Wall Street Sees Strong Upside Potential</h2>According to Koyfin data, four analysts currently cover Vanda. Of those, three rate the stock ‘Buy’ and one rates it ‘Hold’. Price targets range from $7.5 on the low end to $22 on the high end, with a 12-month average target of $13.63, implying an upside of 137% from the stock’s last close.Koyfin data also show that the stock has returned about 28% over the past year.<h2 class="st-heading-2">Bysanti Adds To Vanda’s Psychiatry Portfolio</h2>Bysanti, an atypical antipsychotic, was shown to work in the body the same way as Iloperidone at both lower and higher doses, based on studies of single and repeated dosing, the company said.The approval adds to Vanda’s psychiatry portfolio, which includes Fanapt, already approved for schizophrenia and bipolar I disorder. Fanapt is also being developed as a long-acting injectable formulation for relapse prevention in schizophrenia and is currently in Phase III clinical trials. In its fourth-quarter (Q4) earnings report, Vanda said the global antipsychotic category represented an estimated $20 billion total addressable market in 2025.Beyond bipolar I disorder and schizophrenia, Bysanti is being studied as a once-daily adjunctive treatment in treatment-resistant major depressive disorder. This program is in Phase III development, with the ongoing study expected to be completed by the end of this year.<h2 class="st-heading-2">Vanda Phase 3 GLP-1 Study Planned This Year</h2>In December, the FDA approved Nereus (Tradipitant) for the prevention of motion sickness. Tradipitant is also in Phase II development for vomiting induced by GLP-1 drugs, with Vanda planning to initiate a Phase III program in the first half of 2026. The drug is additionally positioned in the regulatory stage for gastroparesis.Following approval, B. Riley raised its price target on Vanda to $14 from $11 and maintained a ‘Buy’ rating, describing the company as an “ongoing turnaround story” and highlighting the implications for Tradipitant in GLP-1-related nausea. Cantor Fitzgerald maintained an ‘Overweight’ rating with an $11 target, citing the broad label and potential read-through for the GLP-1 nausea program. Jefferies raised its target to $7.50 from $5 while keeping a ‘Hold’ rating, saying Tradipitant could represent a $100 million to $300 million opportunity in motion-related vomiting.<h2 class="st-heading-2">Skin Disease Filing Adds 2026 Catalyst</h2>Imsidolimab, Vanda’s candidate for generalized pustular psoriasis, is in regulatory review following the submission of a biologics license application in Q4. The company has requested priority review, which could allow for a regulatory decision as early as mid-2026 if granted.The filing adds another potential FDA decision point to Vanda’s 2026 calendar, alongside Bysanti’s commercial launch and tradipitant’s Phase III initiation.<h2 class="st-heading-2">Hetlioz Still Advances In Other Sleep Uses</h2>In January, the FDA rejected Vanda’s supplemental application seeking approval of Hetlioz for jet lag disorder in its current form, citing concerns that the study design did not sufficiently reflect real-world jet travel conditions.H.C. Wainwright said the rejection represented only a minor setback and reiterated a ‘Buy’ rating with a $22 price target, noting that its valuation did not include any contribution from tasimelteon sales in jet lag.&nbsp;Hetlioz remains positioned across other sleep indications, with jet lag disorder and insomnia in the regulatory stage and pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24 in Phase III development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for VNDA was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vnda_ss_png_ae74367548.webp" alt="vnda ss.png" width="971" height="139"><figcaption>VNDA sentiment and message volume as of February 22 | Source: Stocktwits</figcaption></figure>One user noted, “More than doubled my position after Nereus was approved taking my average from just under $5 to just under $6.”<stembedurl>https://stocktwits.com/Its_Only_Money_369/message/645576317</stembedurl>Another user said, “could do witha big volume spike monday premarket but everything else looking great.”<stembedurl>https://stocktwits.com/Trapdoor26/message/645559088</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has declined 35% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains?

Shares of Vanda Pharmaceuticals, Inc. (VNDA) jumped over 40% in overnight trading on Sunday after the U.S. Food and Drug Administration (FDA) approved its Bysanti tablets

Vanda said it expects Bysanti to be available in the market in the third quarter of 2026.

<ul class="summary-bullets"><li>The company expects the Bysanti drug to be available in the market in the third quarter of 2026.&nbsp;</li><li>The drug is being tested as a once-daily adjunctive treatment in treatment-resistant major depressive disorder.</li><li>Earlier this year, the FDA refused to approve the company’s application seeking approval of the drug Hetlioz in treating jet lag.</li></ul>Shares of Vanda Pharmaceuticals Inc. (VNDA) rose 38% after hours on Friday after the U.S. Food and Drug Administration approved the company’s Bysanti tablets for the treatment of certain mental health conditions.The FDA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-approval-of-bysanti-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia---a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation-302693941.html">approved</a> the drug for acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia in adults. The company expects the drug to be available in the market in the third quarter of 2026.Bysanti belongs in the class of atypical antipsychotics and demonstrated <a href="https://stocktwits.com/news-articles/markets/equity/vanda-stock-draws-heavy-buzz-ahead-of-fda-verdict-on-bysanti-for-bipolar-schizophrenia/cZRjVwAR4wW">bioequivalence</a> to another schizophrenia drug called Iloperidone at both low and high doses, across single- and multiple-dose studies.It is also now being tested as a once-daily adjunctive treatment in treatment-resistant major depressive disorder. The ongoing study is expected to be completed by the end of this year.<h2 class="st-heading-2">Vanda’s Pipeline</h2>Bysanti is the second Vanda drug to be approved in the span of a few months — its Nereus drug was approved in December for the prevention of motion sickness.However, in early January, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/why-vnda-stock-falling-premarket/cmUbEA9R4Pn">refused</a> to approve the company’s application seeking approval of the drug Hetlioz in treating jet lag. While the FDA acknowledged positive results from Vanda’s clinical trials, it cited concerns that the controlled phase-advance protocols used in the studies do not fully replicate real-world jet travel conditions, including reduced oxygen pressure, noise, and lighting changes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VNDA stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has gained 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/svra-stock-rises-after-hours-as-fda-grants-priority-review-for-lung-disorder-therapy/cZRNZOUR4xU">SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy</a>Get updates to this developing story directly on Stocktwits.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug

This is the second Vanda drug to be approved in the span of a few months, after the approval of Nereus in December.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VNDA News

VNDAVanda Pharmaceuticals Inc